All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).
To receive Global Research’s Daily Newsletter (selected articles), click here.
Keep an eye on this story folks; there’s something else here.
The FDA decision to block COVID-19 treatment options is very sketchy, and I sense that Florida Governor Ron DeSantis knows the science will not support the Biden administration. This story -when exposed- has the potential to bring down the Biden administration, big time… DeSantis senses it.
Earlier today, Florida Governor Ron DeSantis held a roundtable press conference with physicians, clinicians and other health officials in Florida to denounce the Biden FDA decision to revoke monoclonal antibody treatments as a therapeutic option. The FDA action was not only done without communication, but the decision was also made without study and without any input from the treatment side of the COVID-19 dynamic.
Here’s a brief segment of the DeSantis statement:
The full presser is below and is well worth watching to listen to the doctors who refute the FDA claim that monoclonal treatments do not assist patients with Omicron variant. Doctors have treated Omicron patients successfully with the monoclonal antibody treatments. The actual doctors who are treating the patients refute the FDA directly.
The input from Dr. Dwight Reynolds is very revealing. Something is very odd around this story.
UPDATE: I have located the data used to make the decision to get rid of antibody treatment.
It is a *single* non-peer-reviewed study that is not publicly available, written by an author whose name the NIH would not reveal.
Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.
Featured image is from TLR
Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article.
